Table 3.
Organ system specific major congenital malformations in pregnancies of second-generation antipsychotic users. Comparisons to unexposed
| Exposure | Cardiovascular | Central nervous system | Respiratory tract | Orofacial cleft | Gastrointestinal | Urogenital | Musculoskeletal | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | Prev 1/1000 | Adj. OR (95% CI) | |
| Unexposed | 16.9 | Ref | 2.1 | Ref | 0.9 | Ref | 1.5 | Ref | 2.0 | Ref | 5.7 | Ref | 10.4 | Ref |
| Any S-GA | 22.0 | 0.92 (0.62–1.36) | 2.3 | 0.44 (0.13–1.53) | 0.3 | 0.12 (0.01–2.11) | 1.7 | 0.36 (0.07–1.80) | 2.0 | 0.37 (0.09–1.45) | 7.8 | 0.88 (0.45–1.72) | 12.4 | 0.95 (0.58–1.57) |
| Quetiapine | 20.6 | 0.94 (0.61–1.43) | 2.3 | 0.53 (0.15–1.91) | 0.0 | NA | 0.8 | 0.20 (0.02–1.64) | 0.8 | 0.16 (0.02–1.11) | 7.6 | 0.93 (0.45–1.88) | 10.3 | 0.67 (0.38–1.19) |
| Olanzapine | 31.5 | 1.83 (0.74–4.52) | 4.8 | 1.00 (0.08–12.6) | 2.4 | 1.43 (0.04–46.2) | 4.8 | 1.25 (0.07–21.6) | 4.8 | 4.33 (0.63–29.6) | 9.7 | 2.88 (0.71–11.6) | 19.4 | 3.71 (1.35–10.1) |
| Risperidone | 12.4 | 0.74 (0.20–2.78) | 4.1 | 1.00 (0.06–15.7) | 0.0 | NA | 4.1 | 4.76 (0.48–47.1) | 4.1 | 1.19 (0.08–18.0) | 8.3 | 1.23 (0.19–7.89) | 16.5 | 2.77 (0.92–8.29) |
| Aripiprazole | 50.0 | 1.94 (0.58–6.53) | 0.0 | NA | 0.0 | NA | 4.5 | 3.69 (0.06–216.4) | 4.5 | 1.96 (0.04–94.5) | 9.1 | 4.35 (0.62–30.6) | 13.6 | 1.21 (0.19–7.77) |
Analyses based on imputed data
S-GA second-generation antipsychotic, Prev prevalence, Adj. OR adjusted odds ratio adjusted for year of delivery and covariates associated with exposure outcome at P < 0.1
Statistically significant results written in bold